Co-morbidities

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Giuseppe Rosano , David Quek , Felipe Martínez ,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Ovidiu Chioncel , Sean P Collins , Andrew P Ambrosy , et al

Jelena Celutkiene , Mindaugas Balčiūnas , Denis Kablučko , et al

The PRESERVED-HF Study

Mikhail Kosiborod,

Carine E Hamo , Michelle W Bloom ,

Eilidh Hill , Jackie Taylor ,

Umar Ismail , Kiran Sidhu , Shelley Zieroth ,

Mauro Gori , Emilia D’Elia , Edoardo Sciatti , et al

Ovidiu Chioncel , Sean P Collins , Stephen J Greene , et al

Watch Now

Yassir Javaid,

About

Comorbidities frequently accompany chronic heart failure, contributing to increased morbidity and mortality, and an impaired quality of life. Extreme comorbidity is significantly more common in patients with chronic heart failure due to left ventricular systolic dysfunction. The efficient management of such complexity requires the integration of general and specialist expertise.

Media

Giuseppe Rosano, Richard Henry P. Tiongco, Rungroj Krittayaphong, et al

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 13.42 (4 videos)

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Lars H Lund, James L Januzzi, Justin Ezekowitz, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, , , et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Andrew JS Coats, Harriette Van Spall, Faiez Zannad, et al

Shelley Zieroth, Stefan Anker,

EASD 2019: The DEFINE-HF trial - Dr Mikhail N Kosiborod

Mikhail Kosiborod,

Media

Giuseppe Rosano, Richard Henry P. Tiongco, Rungroj Krittayaphong, et al

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 13.42 (4 videos)
HF 22: SCD Risk Protection for Newly Diagnosed HF Patients

José González-Costello,

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Lars H Lund, James L Januzzi, Justin Ezekowitz, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, , , et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

John JV McMurray, Stefan Anker, , et al

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

AHA 2020: EMPA-TROPISM Trial Results — Dr Juan Badimon

Andrew JS Coats, Harriette Van Spall, Faiez Zannad, et al

ESC 2020: Commentary on the EMPEROR-Reduced Study — Dr Giuseppe Galati

Giuseppe Galati,

Shelley Zieroth, Stefan Anker,

HFA 2020: Dapagliflozin and diuretic use in patients with HFrEF in DAPA-HF

Alice Jackson,

Mikhail Kosiborod, Mark Petrie,

HFA 2020: Prospective analysis of DAPA-HF

EASD 2019: The DEFINE-HF trial - Dr Mikhail N Kosiborod

Mikhail Kosiborod,

DAPA-HF: A discussion with the trialist

John JV McMurray, Mikhail Kosiborod,

Articles

SGLT2i in HFpEF

Mauro Gori

,

Emilia D’Elia

,

Edoardo Sciatti

,

Michele Senni

,

Published:

08 July 2022

Citation:

Cardiac Failure Review 2022;8:e26.

DOI:

https://doi.org/10.15420/cfr.2022.04
  • Views: Views 1548
  • Downloads: Downloads 137

Medical Treatment of HFrEF in the Elderly

Ivan Milinkovic

,

Marija Polovina

,

Andrew JS Coats

,

Giuseppe Rosano

,

Petar M Seferovic

,

Published:

09 May 2022

Citation:

Cardiac Failure Review 2022;8:e17.

DOI:

https://doi.org/10.15420/cfr.2021.14
  • Views: Views 1418
  • Downloads: Downloads 143

Heart Failure Therapy in Older Patients

Davide Stolfo

,

Gianfranco Sinagra

,

Gianluigi Savarese

,

Published:

28 April 2022

Citation:

Cardiac Failure Review 2022;8:e16.

DOI:

https://doi.org/10.15420/cfr.2021.34
  • Views: Views 871
  • Downloads: Downloads 116

The Impact of Frailty and Comorbidities on Heart Failure Outcomes

Thomas Salmon

,

Hani Essa

,

Behnam Tajik

,

Masoud Isanejad

,

Asangaedem Akpan

,

Rajiv Sankaranarayanan

,

Published:

21 March 2022

Citation:

Cardiac Failure Review 2022;8:e07.

DOI:

https://doi.org/10.15420/cfr.2021.29
  • Views: Views 674
  • Downloads: Downloads 60